Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...
This is read by an automated voice. Please report any issues or inconsistencies here. Scroll through the deceivingly “endless” options on streaming sites — all of them at the touch of a button — and ...
SINGAPORE, April 20, 2026 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the approval of ZEPZELCA® (lurbinectedin), in combination with atezolizumab ...
It’s been half a century since the VHS (Video Home System) tape was introduced to the world, allowing movie lovers to watch their favorite flicks on demand for the first time. We kept playing (and ...
Ayyoun is a staff writer who loves all things gaming and tech. His journey into the realm of gaming began with a PlayStation 1 but he chose PC as his platform of choice. With over 6 years of ...
A researcher working at Kite, a Gilead Company. Kite’s parent company Gilead Sciences has agreed to acquire Arcellx for $7.8 billion, in a deal intended to give the buyer full control of the buyout ...
“Subscription fatigue,” frustration with streaming content changes, and a desire to collect rare finds are all boosting old-school physical media. The trio of 20-somethings who were happily sifting ...
A new study exploring the investigational therapy, Zorpo-cel, met its primary safety and secondary efficacy endpoints in people with progressive and treatment-resistant systemic sclerosis (SSc), ...
Updated: A full breakdown of all electric vehicle sales by month in Australia in 2026. Latest data includes results for April ...
Julián F.L. is a video game & anime expert, historian & journalist with a lot of passion for these subjects and over 10 years of experience in writing about them. He has enjoyed video games, anime, ...
More than a third of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with the CAR T-cell therapy obecabtagene autoleucel (obe-cel) remained in remission at a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results